Pharmacoepidemiology and Drug Safety

Papers
(The H4-Index of Pharmacoepidemiology and Drug Safety is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Issue Information84
55
Correction to “Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain”49
Management of epilepsy in Lebanon: Medication reviews and drug‐related problems44
Validation of diagnosis codes for chorioamnionitis in medical encounter data, 2013–201835
Predicting obesity and smoking using medication data: A machine‐learning approach31
Quantitative Benefit–Risk Assessment of Vaccination Against COVID‐19: A Systematic Review31
Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research+31
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark31
Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries29
Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data29
Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic Review27
Issue Information26
Letter to the Editor25
External validity in distributed data networks25
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer21
Data Resource Profile: The Danish National Hospital Medicine Register20
Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research20
International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries20
Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study19
ORAL PRESENTATION19
Issue Information19
0.23812198638916